Zenas Biopharma (ZBIO) revenue and earnings history
Zenas Biopharma reported revenue of $10M for fiscal 2025 (year ended Dec 31, 2025), +100.0% on the year before, and net income of −$378M.
Over 2 years, from fiscal 2023 to fiscal 2025, revenue grew at a compound rate of −55.3% a year.
Revenue and net income, 3 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $10M+100.0% | −$383M | −$378M | −$172M | $18K | −$172M | $26.3M | — | — | $111M | $78.6M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Zenas Biopharma (ZBIO) on OQRO.
Common questions
What was Zenas Biopharma's revenue in fiscal 2025?
$10M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 16, 2026. That is +100.0% on fiscal 2024 ($5M).
How fast has Zenas Biopharma's revenue grown?
From $50M in fiscal 2023 to $10M in fiscal 2025: a compound annual growth rate of −55.3% over 2 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Zenas Biopharma been profitable?
It reported a net loss in 3 of the years shown (2023, 2024, 2025). The highest net income was −$37.1M in fiscal 2023.
Where these figures come from
The SEC’s companyfacts data: every figure Zenas Biopharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
